CTLA4 and melanoma: Indeed, ipilimumab, which blocks CTLA-4, was the first immune checkpoint antibody approved by the FDA for treatment of melanoma, and ICIs have become the standard of care in multiple different cancer types, including renal cell carcinoma (23–25).